Larimar Therapeutics, Inc. (LRMR) — Executive Compensation
Fiscal year ended December 2025
This page summarizes Larimar Therapeutics, Inc. (LRMR) named executive officer compensation from the most recent SEC DEF 14A proxy statement. Dr. Ben-Maimon (CEO) received $3,526,423 in reported total compensation@if($peoPaid !== null), with $2,137,100 "actually paid" under the SEC pay-versus-performance rule. @endif Total shareholder return for the period was 36.24.
Frequently asked questions
Who is the CEO of LRMR and how much are they paid?
Dr. Ben-Maimon serves as CEO of Larimar Therapeutics, Inc.. For fiscal year ending December 2025, reported total compensation was $3,526,423.
What is included in executive compensation?
SEC Summary Compensation Table figures include base salary, cash bonuses, stock awards (grant-date fair value), option awards, non-equity incentive plan compensation, pension value changes, and all other compensation. "Actually Paid" compensation follows the newer SEC pay-versus-performance rule and reflects realized value.
What is pay-versus-performance?
The SEC pay-versus-performance disclosure requires companies to show the relationship between executive pay "actually paid" and total shareholder return (TSR) over recent fiscal years, so investors can evaluate pay alignment.